2019冠状病毒病患者甘草酸二铵预防性保肝治疗的临床价值  

Clinical value of prophylactic liver protecting drugs in coronavirus disease 2019(COVID-19)

作　　者：孙信林 张睿[2] 李雨松[3] 赵丽君 SUN Xinlin;ZHANG Rui;LI Yusong;ZHAO Lijun(Department of Respiratory Medicine,Huai′an Fourth People′s Hospital,Huai′an,Jiangsu 223001,China;Department of Hepatology,Huai′an Fourth Pople′s Hospital;Department of Laboratory,Huai′an Fourth People′s Hospital;Department of Medicinal Materials,Huai′an Tumor Hospital,Huai′an,Jiangsu 223200)

机构地区：[1]淮安市第四人民医院呼吸科,江苏淮安223001 [2]淮安市第四人民医院肝病科 [3]淮安市第四人民医院检验科 [4]淮安市肿瘤医院药材科,江苏淮安223200

出　　处：《徐州医科大学学报》2020年第4期293-296,共4页Journal of Xuzhou Medical University

摘　　要：目的探讨并分析2019冠状病毒病(coronavirus disease 2019,COVID-19)患者肝损伤发生情况及甘草酸二铵预防性保肝治疗的临床价值。方法收集2020年1月23日—3月9日淮安市确诊的COVID-19患者66例,随机分为观察组(n=34)和对照组(n=32)。观察组给予抗病毒治疗、对症治疗及甘草酸二铵肠溶胶囊预防性保肝治疗,对照组仅给予抗病毒治疗和对症治疗。观察2组治疗前、治疗1周、治疗2周的肝功能指标〔丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、碱性磷酸酶(ALP)、γ-谷氨酰转肽酶(GGT)〕的变化。结果2组患者在治疗前ALT、AST水平差异无统计学意义(P>0.05);治疗1周及2周以后,观察组ALT、AST水平均较对照组降低,差异有统计学意义(P<0.05)。2组患者在治疗前、治疗1周及2周后ALP、GGT水平差异均无统计学意义(P>0.05)。结论甘草酸二铵预防性保肝治疗对COVID-19患者的肝功能具有保护作用。Objective To explore and analyze the incidence of liver injury in patients with coronavirus disease 2019(COVID-19)and the clinical value of diammonium glycyrrhizinate preventive liver protection.Methods A total of 66 patients with COVID-19 diagnosed in Huai′an from January 23 to March 9,2020 were randomly divided into observation group(n=34)and control group(n=32).The observation group was given antiviral treatment,symptomatic treatment and diammonium glycyrrhizinate enteric coated capsule prophylactic liver protection treatment,while the control group was only given antiviral treatment and symptomatic treatment.The changes of liver function indexes\were observed before treatment,and at 1 week and 2 weeks after treatment.Results There was no significant difference in ALT and AST levels between the two groups before treatment(P>0.05);At 1 week and 2 weeks after treatment,the levels of ALT and AST were significantly lower in the observation group than in the control group(P<0.05).There was no significant difference in ALP and GGT between the two groups before treatment and at 1 week and 2 weeks after treatment(P>0.05).Conclusions Diammonium glycyrrhizinate has protective effect on liver function of patients with covid-19.

关 键 词：2019冠状病毒病 新型冠状病毒肺炎 炎症反应 肝损伤 甘草酸二铵 预防性保肝治疗 

分 类 号：R563.14[医药卫生—呼吸系统]